NCT05748366 Ultrasound Guided Serratus Anterior Plane Block for Rib Fractures
| NCT ID | NCT05748366 |
| Status | Recruiting |
| Phase | — |
| Sponsor | WellSpan Health |
| Condition | Rib Fracture Multiple |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-03-31 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2023-03-31 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a single center, randomized controlled trial examining the effect of serratus anterior plane block (SAPB) on pain, PIC scores and other clinical outcomes in emergency department patients with multiple rib fractures in comparison to the use of analgesic medication alone. Objectives 1. Compare SAPB performed in the ED setting to analgesic medication alone with regard to pain, respiratory status and PIC score of patients with multiple rib fractures. 2. Assess the safety and feasibility of performing ultrasound-guided SAPB in the ED. 3. Evaluate outcomes of patients receiving the SAPB in the ED including amount of analgesic medications used, level of care required, need for upgrading level of care, and length of stay.
Eligibility Criteria
Inclusion Criteria: * Age \>18 years * \>1 Unilateral, acute rib fractures diagnosed on x-ray or CT imaging * Patient presenting to the WellSpan York Hospital ED * Patient requiring IV analgesia or oral opioid to control pain related to rib fractures Exclusion Criteria: * Age \<18 years * Inability to provide informed consent * Allergy to local anesthesia * Subsequent visit for rib fractures * Patients taken emergently to the OR or discharged from the ED * Significant distracting injuries/polytrauma that would not be expected to be responsive to analgesia from SAPB and confound pain scores, i.e. long bone fractures, intraabdominal injuries, etc.
Contact & Investigator
Daniel Kreider, MD
PRINCIPAL INVESTIGATOR
WellSpan Health
Frequently Asked Questions
Who can join the NCT05748366 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rib Fracture Multiple. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05748366 currently recruiting?
Yes, NCT05748366 is actively recruiting participants. Contact the research team at dkreider3@wellspan.org for enrollment information.
Where is the NCT05748366 trial being conducted?
This trial is being conducted at York, United States.
Who is sponsoring the NCT05748366 clinical trial?
NCT05748366 is sponsored by WellSpan Health. The principal investigator is Daniel Kreider, MD at WellSpan Health. The trial plans to enroll 60 participants.